Summary:
- Alector, a biotechnology company, has announced the topline results from its Phase 3 clinical trial of latozinemab, a drug candidate for the treatment of frontotemporal dementia (FTD).
- The trial evaluated the safety and efficacy of latozinemab in patients with FTD, a type of progressive brain disorder that affects language, behavior, and personality.
- The results showed that latozinemab met the primary endpoint, demonstrating a statistically significant slowing of disease progression in FTD patients compared to the placebo group.